Compare Illumina, Inc. (ILMN) vs Orion Office REIT Inc (ONL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Illumina, Inc. vs Orion Office REIT Inc — how do they compare? Illumina, Inc. trades at $268.33 (market cap $39.95B), while Orion Office REIT Inc trades at $2.18 (market cap $125.50M). The key difference: Illumina, Inc. is far larger — about 318.3× Orion Office REIT Inc's market cap, and Orion Office REIT Inc pays a 3.64% dividend while Illumina, Inc. pays none. Which is the better fit depends on your goals — on Pluang, investors hold Illumina, Inc. for 83 Days and Orion Office REIT Inc for 33 Days on average.
| ILMN | ONL | |
|---|---|---|
Market Cap | $39.95B | $125.50M |
Volume | 3,169,503 | 303,276 |
Sector | Health | Real Estate |
52-Week High | $293.69 | $3.00 |
52-Week Low | $91.00 | $1.93 |
Typical Hold Time | 83 Days | 33 Days |
Enterprise Value | $41.31B | $542.43M |
Dividend Yield | — | 3.64% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Illumina (ILMN) trades at $267.76, down 2.11% today but remains near recent highs after a strong 94.9% YTD rally. The stock shows bullish technical momentum with recent earnings beats and improved profitability, with net income turning positive to $850 million in 2025 after previous losses. S&P 500 inclusion in September 2026 and growing AI integration in genomics provide positive catalysts, though valuation metrics remain elevated with a P/E of 49.36.
Outlook remains positive with analyst consensus favoring Buy ratings (54%) and a $241 price target, though current price exceeds consensus. Key opportunities include sequencing growth and AI adoption, while risks include China headwinds, margin pressure, and high valuation multiples requiring sustained execution to justify premium pricing.
ONL trades at $2.19, down 3.52% today, with a bearish technical signal despite a recent earnings beat. The REIT shows declining revenue from $208M in 2022 to $148M in 2025, with persistent net losses widening to -$139M. Positive cash flow of $3.47M in 2025 and a low P/B of 0.2 offer value, but high debt and negative margins pose challenges. Analysts are split 50/50 between Buy and Hold.
Outlook remains cautious; deep discount to book value and strategic portfolio repositioning may attract value investors, but sustained losses and office sector headwinds limit near-term upside. Key risks include leverage pressure and execution of turnaround plans amid weak demand.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Illumina, Inc.
Illumina provides tools and services to analyze genetic material with life science and clinical lab applications. The company generates over 90% of its revenue from sequencing instruments, consumables, and services. Illumina's high-throughput technology enables whole genome sequencing in humans and other large organisms. Its lower throughput tools enable applications that require smaller data outputs, such as viral and cancer tumor screening. Illumina also sells microarrays (less than 10% of sales) that enable lower-cost, focused genetic screening with primarily consumer and agricultural applications.
Read more on ILMN →About Orion Office REIT Inc
Orion Office REIT Inc is a internally-managed REIT engaged in the ownership, acquisition, and management of a diversified portfolio of mission-critical and headquarters office buildings located in high quality suburban markets across the U.S. and leased primarily on a single-tenant net lease basis to creditworthy clients.
Read more on ONL →
